We reply within one business dayGet my quote
Tuberous sclerosis complex (TSC): US-approved treatments and how Gulf families can access them
A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Tuberous sclerosis complex: the short answer
The US FDA has approved two medicines on this page for tuberous sclerosis complex, each for specific patients. Two of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.
- US FDA-approved medicines on this page: Afinitor and Hyftor.
- Gulf registration (checked 17 October 2026): see each medicine below.
- Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital.
- Price: Quote on request.
What is tuberous sclerosis complex?
Tuberous sclerosis complex (TSC) is a genetic disorder that causes many noncancerous tumors in the brain, kidneys, heart, skin, eyes and other organs. Signs and severity vary widely.[1]
Seizures, developmental problems and TSC-associated neuropsychiatric disorders (TAND), such as hyperactivity and autism spectrum disorder, are common. Kidney tumors can threaten kidney function. Almost everyone has skin changes, including light patches and facial angiofibromas, which often begin in childhood.[1]
TSC has no cure, but treatments help symptoms, including medicines, therapy and surgery for complications. In the US, an mTOR inhibitor is approved for TSC-related brain tumors (SEGA), kidney tumors and seizures, and a sirolimus gel is approved for facial angiofibroma.[2, 3, 4]
Tuberous sclerosis complex in the Gulf
A review of 61 genetically confirmed TSC patients at National Guard Health Affairs in Saudi Arabia found a mean age at diagnosis of 4.9 years. 86.9% had epilepsy, half of it hard to control with medicines, and TSC2 changes were more common than TSC1.[5]
US FDA-approved medicines for tuberous sclerosis complex
Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.
- Afinitor (everolimus)
FDA-approved for adults and children 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) needing treatment, adults with TSC-related renal angiomyolipoma not needing immediate surgery, and TSC-associated partial-onset seizures (Afinitor Disperz), as listed in the label. It is taken by mouth.[3]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7] - Hyftor (sirolimus)
FDA-approved for facial angiofibroma associated with tuberous sclerosis in adults and children 6 years and older. It is a gel applied to the skin.[4]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.[6, 7]
How families in the Gulf can access these medicines
If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.
If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.[8, 9] Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.
Who does what
- Your treating specialist decides whether a medicine is right for the patient and writes the letter.
- The hospital checks local supply, files any import request, and gives the treatment safely.
- The national regulator decides whether to approve the import of a medicine that is not registered.
- The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
- Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.
Documents you will usually need
- A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
- Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
- Recent clinic notes and a list of current medicines
- For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
- Proof of the US FDA approval and the US prescribing information (we can supply these)
We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.
What treatment costs
Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.
Ask us about treatment for tuberous sclerosis complex
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is there an FDA-approved treatment for tuberous sclerosis complex?
Yes. The medicines on this page have US FDA approval for specific groups of patients: Afinitor and Hyftor. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.
Is Afinitor available in Saudi Arabia or the UAE?
Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.
How can a family in the Gulf get Afinitor?
Ask the treating hospital about local supply first. If it is not available, the hospital can file a named-patient import request with the national regulator on your specialist's written request. Once approved, we arrange US supply to the hospital pharmacy.
How much does treatment cost?
Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Why is epilepsy care so important in TSC?
In the Saudi cohort, 86.9% of patients had epilepsy and half of those had seizures that were hard to control with medicines. Regular neurology follow-up is key.
What are facial angiofibromas?
They are small growths on the face that commonly begin in childhood in TSC, as MedlinePlus Genetics explains. A sirolimus gel is approved in the US to treat them.
Sources for the last two answers: [5] [1, 4]
Sources
Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.
- MedlinePlus Genetics (US National Library of Medicine): Tuberous sclerosis complex
- MedlinePlus (US National Library of Medicine): Tuberous Sclerosis
- DailyMed (US National Library of Medicine): Afinitor (everolimus) US prescribing information, version published 11 June 2026
- DailyMed (US National Library of Medicine): Hyftor (sirolimus) US prescribing information, version published 25 August 2025
- Almuqbil et al. Review of the spectrum of tuberous sclerosis complex: The Saudi Arabian Experience. Neurosciences (Riyadh) 2024 (PubMed 38740395)
- SFDA: Drugs List, public register (all 9,173 entries checked by brand name on 17 October 2026)
- Department of Health Abu Dhabi: drug code list Drugs.xlsx (release 26 September 2026, effective 2 October 2026)
- SFDA: Special Access Program (SAP) guidance, version 1.0
- NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
Related
- Rett syndrome
- Renal cell carcinoma
- Named-patient access in the Gulf, explained
- Answers to common access questions
- Cross-border disclosures
- اقرأ هذه الصفحة بالعربية
This page is general health information, not medical advice. It does not replace a consultation with your doctor.